Pomanda estimates the enterprise value of BARCLAY PHARMACEUTICALS LIMITED at £31m based on a Turnover of £63.7m and 0.49x industry multiple (adjusted for size and gross margin).
Pomanda estimates the enterprise value of BARCLAY PHARMACEUTICALS LIMITED at £3.8m based on an EBITDA of £840k and a 4.52x industry multiple (adjusted for size and gross margin).
Pomanda estimates the enterprise value of BARCLAY PHARMACEUTICALS LIMITED at £50.4m based on Net Assets of £26.7m and 1.89x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Barclay Pharmaceuticals LimitedOverview
Barclay Pharmaceuticals Limited is a live company located in warwick, CV34 5AH with a Companies House number of 02770716. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in December 1992, it's largest shareholder is
aah pharmaceuticals limited
with a 100% stake. Barclay Pharmaceuticals Limited is a mature,
large sized company, Pomanda has estimated its turnover at
£63.7m with
declining
growth in recent years.
Pomanda's financial health check has awarded Barclay Pharmaceuticals Limited a 3 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 4 areas for improvement. Company Health Check FAQs
Health Rating3out of 5
3 Strong
3 Regular
4 Weak
Size
annual sales of £63.7m, make it larger than the average company (£25.3m)
£63.7m - Barclay Pharmaceuticals Limited
£25.3m - Industry AVG
Growth
3 year (CAGR) sales growth of -38%, show it is growing at a slower rate (5.6%)
-38% - Barclay Pharmaceuticals Limited
5.6% - Industry AVG
Production
with a gross margin of 1.8%, this company has a higher cost of product (26.2%)
1.8% - Barclay Pharmaceuticals Limited
26.2% - Industry AVG
Profitability
an operating margin of 1.3% make it less profitable than the average company (3.8%)
1.3% - Barclay Pharmaceuticals Limited
3.8% - Industry AVG
Employees
with 97 employees, this is above the industry average (38)
97 - Barclay Pharmaceuticals Limited
38 - Industry AVG
Pay Structure
on an average salary of £74.5k, the company has an equivalent pay structure (£74.5k)
£74.5k - Barclay Pharmaceuticals Limited
£74.5k - Industry AVG
Efficiency
resulting in sales per employee of £656.4k, this is equally as efficient (£658.5k)
£656.4k - Barclay Pharmaceuticals Limited
£658.5k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Barclay Pharmaceuticals Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 3 days, this is quicker than average (32 days)
3 days - Barclay Pharmaceuticals Limited
32 days - Industry AVG
Stock Days
it holds stock equivalent to 49 days, this is in line with average (61 days)
49 days - Barclay Pharmaceuticals Limited
61 days - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Barclay Pharmaceuticals Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 2.4%, this is a lower level of debt than the average (55%)
2.4% - Barclay Pharmaceuticals Limited
55% - Industry AVG
BARCLAY PHARMACEUTICALS LIMITED financials
EXPORT
Barclay Pharmaceuticals Limited's latest turnover from March 2024 is £63.7 million and the company has net assets of £26.7 million. According to their latest financial statements, we estimate that Barclay Pharmaceuticals Limited has 97 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Turnover
63,666,000
83,086,000
335,908,000
264,438,000
250,191,000
255,948,000
281,372,000
297,130,000
285,003,000
339,760,000
246,807,000
232,224,000
287,238,000
276,924,000
237,744,000
Other Income Or Grants
Cost Of Sales
62,508,000
81,724,000
318,271,000
250,951,000
233,485,000
243,380,000
267,916,000
282,299,000
265,340,000
308,688,000
226,504,000
211,329,000
265,246,000
254,347,000
217,976,000
Gross Profit
1,158,000
1,362,000
17,637,000
13,487,000
16,706,000
12,568,000
13,456,000
14,831,000
19,663,000
31,072,000
20,303,000
20,895,000
21,992,000
22,577,000
19,768,000
Admin Expenses
318,000
1,159,000
14,069,000
13,251,000
13,353,000
13,753,000
14,310,000
15,076,000
15,354,000
19,878,000
13,631,000
11,342,000
13,459,000
13,584,000
14,325,000
Operating Profit
840,000
203,000
3,568,000
236,000
3,353,000
-1,185,000
-854,000
-245,000
4,309,000
11,194,000
6,672,000
9,553,000
8,533,000
8,993,000
5,443,000
Interest Payable
268,000
325,000
370,000
375,000
372,000
442,000
589,000
508,000
443,000
430,000
399,000
437,000
Interest Receivable
125,000
Pre-Tax Profit
518,000
203,000
3,568,000
-32,000
3,028,000
-1,555,000
-1,229,000
-617,000
3,867,000
10,605,000
6,164,000
9,110,000
8,103,000
8,594,000
5,131,000
Tax
640,000
-677,000
-15,000
-549,000
292,000
231,000
119,000
-574,000
-2,266,000
-1,429,000
-2,248,000
-2,174,000
-2,426,000
-1,456,000
Profit After Tax
518,000
843,000
2,891,000
-47,000
2,479,000
-1,263,000
-998,000
-498,000
3,293,000
8,339,000
4,735,000
6,862,000
5,929,000
6,168,000
3,675,000
Dividends Paid
74,000,000
Retained Profit
-73,482,000
843,000
2,891,000
-47,000
2,479,000
-1,263,000
-998,000
-498,000
3,293,000
8,339,000
4,735,000
6,862,000
5,929,000
6,168,000
3,675,000
Employee Costs
7,227,777
725,882
6,349,000
6,273,000
6,551,000
6,543,000
7,220,000
7,750,000
8,134,000
10,522,000
6,559,000
5,325,000
6,240,000
6,444,000
6,874,000
Number Of Employees
97
10
316
318
326
323
338
376
411
435
349
285
300
299
331
EBITDA*
840,000
203,000
3,568,000
236,000
3,353,000
-1,185,000
-854,000
-245,000
4,309,000
11,194,000
6,672,000
9,553,000
8,533,000
8,993,000
5,443,000
* Earnings Before Interest, Tax, Depreciation and Amortisation
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Tangible Assets
30,000
34,000
22,000
30,000
33,000
37,000
24,000
59,000
39,000
50,000
55,000
56,000
Intangible Assets
Investments & Other
20,000
Debtors (Due After 1 year)
15,000
17,000
Total Fixed Assets
15,000
17,000
20,000
22,000
30,000
33,000
37,000
24,000
59,000
39,000
50,000
55,000
56,000
Stock & work in progress
8,550,000
8,610,000
7,457,000
47,678,000
45,281,000
44,707,000
38,679,000
53,983,000
49,198,000
39,183,000
35,071,000
32,190,000
46,234,000
39,714,000
34,082,000
Trade Debtors
132,376,000
18,846,000
18,406,000
15,369,000
15,307,000
2,994,000
2,886,000
79,000
707,000
25,521,000
25,250,000
28,806,000
24,160,000
Group Debtors
18,794,000
92,027,000
63,616,000
51,793,000
53,037,000
68,019,000
68,479,000
72,362,000
75,458,000
71,723,000
39,541,000
33,743,000
21,862,000
34,117,000
Misc Debtors
3,792,000
8,989,000
8,053,000
3,862,000
2,478,000
4,186,000
3,176,000
4,588,000
2,918,000
2,866,000
2,521,000
2,028,000
Cash
2,000
1,000
1,000
45,000
17,000
11,000
55,000
87,000
35,000
misc current assets
657,000
357,000
123,000
total current assets
27,344,000
100,637,000
139,835,000
133,932,000
124,470,000
121,823,000
126,224,000
128,057,000
128,633,000
117,941,000
112,106,000
100,181,000
108,148,000
92,990,000
94,422,000
total assets
27,344,000
100,637,000
139,850,000
133,949,000
124,490,000
121,845,000
126,254,000
128,090,000
128,670,000
117,965,000
112,165,000
100,220,000
108,198,000
93,045,000
94,478,000
Bank overdraft
152,000
Bank loan
Trade Creditors
635,000
32,262,000
28,423,000
26,424,000
23,779,000
27,708,000
30,883,000
30,135,000
19,448,000
23,528,000
16,079,000
31,169,000
21,687,000
29,266,000
Group/Directors Accounts
466,000
1,363,000
other short term finances
hp & lease commitments
other current liabilities
20,000
8,260,000
9,089,000
219,000
4,061,000
3,278,000
941,000
1,771,000
5,046,000
3,505,000
3,744,000
3,494,000
3,752,000
3,622,000
total current liabilities
655,000
466,000
40,522,000
37,512,000
28,006,000
27,840,000
30,986,000
31,824,000
31,906,000
24,494,000
27,033,000
19,823,000
34,663,000
25,439,000
33,040,000
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
total long term liabilities
total liabilities
655,000
466,000
40,522,000
37,512,000
28,006,000
27,840,000
30,986,000
31,824,000
31,906,000
24,494,000
27,033,000
19,823,000
34,663,000
25,439,000
33,040,000
net assets
26,689,000
100,171,000
99,328,000
96,437,000
96,484,000
94,005,000
95,268,000
96,266,000
96,764,000
93,471,000
85,132,000
80,397,000
73,535,000
67,606,000
61,438,000
total shareholders funds
26,689,000
100,171,000
99,328,000
96,437,000
96,484,000
94,005,000
95,268,000
96,266,000
96,764,000
93,471,000
85,132,000
80,397,000
73,535,000
67,606,000
61,438,000
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Operating Activities
Operating Profit
840,000
203,000
3,568,000
236,000
3,353,000
-1,185,000
-854,000
-245,000
4,309,000
11,194,000
6,672,000
9,553,000
8,533,000
8,993,000
5,443,000
Depreciation
Amortisation
Tax
640,000
-677,000
-15,000
-549,000
292,000
231,000
119,000
-574,000
-2,266,000
-1,429,000
-2,248,000
-2,174,000
-2,426,000
-1,456,000
Stock
-60,000
1,153,000
-40,221,000
2,397,000
574,000
6,028,000
-15,304,000
4,785,000
10,015,000
39,183,000
2,881,000
-14,044,000
6,520,000
5,632,000
34,082,000
Debtors
-73,233,000
-40,364,000
46,120,000
7,083,000
2,729,000
-10,729,000
13,237,000
-5,483,000
721,000
78,713,000
9,038,000
6,121,000
8,670,000
-7,116,000
60,305,000
Creditors
635,000
-32,262,000
3,839,000
1,999,000
2,645,000
-3,929,000
-3,175,000
748,000
10,687,000
19,448,000
7,449,000
-15,090,000
9,482,000
-7,579,000
29,266,000
Accruals and Deferred Income
20,000
-8,260,000
-829,000
8,870,000
-3,842,000
783,000
2,337,000
-830,000
-3,275,000
5,046,000
-239,000
250,000
-258,000
130,000
3,622,000
Deferred Taxes & Provisions
Cash flow from operations
74,788,000
-468,000
2,000
1,610,000
-1,696,000
662,000
606,000
490,000
411,000
-84,474,000
534,000
388,000
393,000
602,000
-57,512,000
Investing Activities
capital expenditure
30,000
4,000
-34,000
22,000
8,000
3,000
4,000
-13,000
-24,000
-20,000
11,000
5,000
1,000
-56,000
Change in Investments
-20,000
20,000
cash flow from investments
30,000
4,000
-14,000
2,000
8,000
3,000
4,000
-13,000
-24,000
-20,000
11,000
5,000
1,000
-56,000
Financing Activities
Bank loans
Group/Directors Accounts
-466,000
466,000
-1,363,000
1,363,000
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue
85,132,000
57,763,000
interest
-268,000
-325,000
-370,000
-375,000
-372,000
-442,000
-589,000
-508,000
-443,000
-430,000
-399,000
-312,000
cash flow from financing
-466,000
466,000
-1,631,000
1,038,000
-370,000
-375,000
-372,000
-442,000
84,543,000
-508,000
-443,000
-430,000
-399,000
57,451,000
cash and cash equivalents
cash
-2,000
2,000
-1,000
1,000
-1,000
-44,000
45,000
6,000
-44,000
-32,000
52,000
35,000
overdraft
-152,000
152,000
change in cash
-2,000
2,000
-1,000
1,000
-1,000
-44,000
45,000
6,000
-44,000
-32,000
204,000
-117,000
barclay pharmaceuticals limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for barclay pharmaceuticals limited. Get real-time insights into barclay pharmaceuticals limited's credit score, group structure and payment trends.
Perform a competitor analysis for barclay pharmaceuticals limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other large companies, companies in CV34 area or any other competitors across 12 key performance metrics.
barclay pharmaceuticals limited Ownership
BARCLAY PHARMACEUTICALS LIMITED group structure
Barclay Pharmaceuticals Limited has no subsidiary companies.
The sole shareholder of Barclay Pharmaceuticals Limited is Aah Pharmaceuticals Limited.
aah pharmaceuticals limited
100%
barclay pharmaceuticals limited directors
Barclay Pharmaceuticals Limited currently has 3 directors.
The longest serving directors include
Ms Wendy Hall (Jul 2022) and
Mr David Bound (Dec 2022).
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 11 charges/mortgages relating to barclay pharmaceuticals limited. Currently there are 7 open charges and 4 have been satisfied in the past.
barclay pharmaceuticals limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for BARCLAY PHARMACEUTICALS LIMITED. This can take several minutes, an email will notify you when this has completed.
barclay pharmaceuticals limitedCompanies House Filings - See Documents
